Evidence map›Paper›PMID 30923102›Full record

ArticleHaematologica2019

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia.

Simone Claudiani, Aoife Gatenby, Richard Szydlo, George Nesr, Adi Shacham Abulafia, Renuka Palanicawandar, Georgios Nteliopoulos, Jamshid Khorashad, Letizia Foroni, Jane F Apperley and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. MolecularInternational journal of molecular sciences · 2023
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Simone ClaudianiDepartment of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK simone.claudiani@nhs.net.
Aoife GatenbyCentre for Haematology, Imperial College London, London, UK.
Richard SzydloCentre for Haematology, Imperial College London, London, UK.
George NesrDepartment of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
Adi Shacham AbulafiaInstitute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Rabin Medical Centre, Petah-Tiqva, Israel.
Renuka PalanicawandarDepartment of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
Georgios NteliopoulosCentre for Haematology, Imperial College London, London, UK.
Jamshid KhorashadCentre for Haematology, Imperial College London, London, UK.
Letizia ForoniCentre for Haematology, Imperial College London, London, UK.
Jane F ApperleyDepartment of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
Dragana MilojkovicDepartment of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of patients with newly diagnosed chronic myeloid leukemia (CML) will enjoy a life expectancy equivalent to that of unaffected individuals, but will remain on life-long treatment with a concomitant requirement for on-going hospital interactions for molecular monitoring and drug dispensing. In order to determine more accurately the frequency of monitoring required, we performed a 'real-life' retrospective single-center cohort study of 450 patients with CML in at least major molecular remission (MR3) to analyze the risk of loss of MR3 [defined as at least 2 consecutive real-time quantitative polymerase chain reaction (RT-qPCR) results >0.1% International Scale (IS)]. Patients who achieved sustained MR4 (sMR4, BCR-ABL1 RT-qPCR <0.01% IS for 12 months) had a probability of loss of MR3 at 1 and 5 years of 0 and 2.6% (95%CI: 1.2-5.4) respectively, compared to 4.4% (95%CI: 1.9-9.8) and 25.4% (95%CI: 16.7-36.7) respectively, in those who achieved sustained MR3 (sMR3) but not sMR4 (

Indexed as

Real-Time Polymerase Chain ReactionAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorFemaleFusion Proteins, bcr-ablHumansKaplan-Meier EstimateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPrognosisProtein Kinase InhibitorsTranscription, GeneticBiomarkers, TumorFusion Proteins, bcr-ablProtein Kinase Inhibitors

Identifiers

PMID30923102
PMCPMC6821602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.